Introduction
============

Mammalian platelets are small cell fragments with neither nucleus nor microtubule organizing center. They circulate in the blood stream to survey vascular integrity. In their quiescent state, they have a flat, discoid morphology caused by a microtubular ring structure, called the marginal band (MB), in the periphery of resting platelets ([@bib32]). Endothelial damage will induce platelet activation, which is composed of several successive events ([@bib11]). Within seconds, they adopt a 3D, sphere-shaped morphology, extend filopodia, secrete the content of their granules, and spread on the subendothelial layer or aggregate with surrounding platelets to form a hemostatic plug. In the activated platelet, a smaller microtubule ring structure is observed, and it has been suggested that actomyosin tension leads to the spherical shape and induces the centripetal contraction of the MB ([@bib31]; [@bib13]). So far, microtubule motor proteins have not been implicated in the maintenance of the resting MB, the shape change, or the MB reorganization during platelet activation ([@bib18]; [@bib11]).

MB microtubules in resting platelets are heavily acetylated ([@bib19]). In general, prominent microtubule acetylation is observed when microtubule motor actions are important either for cellular transport processes ([@bib22]; [@bib8]) or for microtubule movements, as for instance, in mitotic spindles, primary cilia, or flagella ([@bib21]; [@bib25]). We therefore hypothesized that microtubule motor proteins might be functionally important in platelets.

Results and discussion
======================

Microtubule motor actions in platelets
--------------------------------------

To investigate whether microtubule motors could play a functional role in platelets, we first performed Western blotting to test for their presence in platelet lysates using pan-anti--kinesin heavy chain and dynein intermediate chain antibodies. Kinesin heavy chains of 68 and 72 kD as well as the dynein intermediate chain of 74 kD were detected in platelet lysates ([Fig. 1 A](#fig1){ref-type="fig"}) as described previously ([@bib23]; [@bib18]). We then treated resting platelets with the dynein inhibitor erythro-9-\[3-2-(hydroxynonyl)\]adenine (EHNA; [@bib20]) and either fixed them in suspension (resting state) or centrifuged them onto glass coverslips to let them spread for 10 min at 37°C as a test for their activation capacity. No obvious alteration of resting platelets is observed after dynein inhibition, whereas spreading is almost completely prevented. Surprisingly, use of the kinesin inhibitor aurintricarboxylic acid (ATA; [@bib9]) in the same assay, results in a smaller microtubule ring in resting platelets, but platelets are still able to spread on a glass surface and do so with a more round morphology ([Fig. 1 B](#fig1){ref-type="fig"} and [Fig. S1, A and B](http://www.jcb.org/cgi/content/full/jcb.201306085/DC1){#supp1}, for quantification).

![**Presence of microtubule motors in platelets and motor inhibitor treatments.** (A) Western blot of 5 µg lysates of the cell line A549 (A), the megakaryocyte precursor line CHRF-288-11 (M), and of 10^7^ platelets (P) revealed with a pan-anti--kinesin heavy chain and an anti--dynein intermediate chain antibody. (B) Resting platelets in PRP from buffy coats were diluted in PBS, 2.5 × 10^6^/ml, and incubated with 1 mM EHNA or 10 µM ATA for 30 min at RT and then either fixed (top; 30' inhibitors/0' spreading) or allowed to spread on a glass surface for 10 min (bottom; 30' inhibitors/10' spreading) before fixation and α-tubulin staining. (C) Control rabbit IgGs as well as mouse anti-dynein and rabbit anti-kinesin function-blocking antibodies were introduced into living platelets using the Chariot kit. Platelets were then allowed to spread on glass coverslips for 10 min, fixed, and stained using a monoclonal rabbit anti α-tubulin antibody for the anti-dynein Chariot and a mouse anti--α-tubulin antibody for the control and the anti-kinesin Chariot conditions (in green) as well as secondary antibodies recognizing the introduced antibodies (anti--mouse for the dynein Chariot and anti--rabbit for the control and the kinesin Chariot conditions, in red). (D) 3D projection of a confocal z stack of platelets treated as in B (top) with 10 µM ATA but for only 3 min, fixed, and stained for acetylated tubulin (acTub). [Video 1](http://www.jcb.org/cgi/content/full/jcb.201306085/DC1){#supp2}. Bars: (B and C) 10 µm; (D) 5 µm.](JCB_201306085_Fig1){#fig1}

These inhibitor experiments suggested that both microtubule motors have a functional role in platelets. To confirm these results, we introduced the kinesin and dynein antibodies, previously shown to be function blocking ([@bib28]; [@bib10]), into resting platelets using the Chariot kit. Dynein antibodies inhibited platelet spreading, resulting in the appearance of a majority of star-shaped platelets, similar to EHNA treatments. After introduction of kinesin antibodies, platelets were able to spread, and a higher number of fully round, spread platelets was observed, again similar to treatments with ATA ([Fig. 1 C](#fig1){ref-type="fig"} and Fig. S1 B, for quantification).

MBs coil during platelet activation
-----------------------------------

Activated platelets have smaller microtubule rings than nonactivated platelets, and it has been suggested that this is caused by MB contraction ([@bib31]). Because kinesin inhibition leads to a smaller microtubule ring ([Fig. 1 B](#fig1){ref-type="fig"}, top), we wondered whether kinesin inhibition could trigger MB contraction. Thus, platelets were treated with ATA for a shorter time period (3 min), fixed in suspension, and stained for tubulin (not depicted) or acetylated tubulin ([Fig. 1 D](#fig1){ref-type="fig"}). Half of the platelets (48.4 ± 6.1%) still had the characteristic flat MB of resting platelets, and 22.8 ± 5.5% had a smaller ring. To our surprise, we observed in the remaining 28.8 ± 8.3% a 3D twist of the MB (four independent experiments). Platelets with coiled MBs had lost their disc shape and were more spherical. Thus, MB coiling induced by kinesin inhibition results in a disc to sphere transition and ultimately in a smaller microtubule ring structure, two hallmarks of activating platelets. We thus wondered whether MB coiling is the molecular mechanism leading to sphere shape during platelet activation. If so, it should be possible to detect MB coiling under physiological conditions.

Immediately after, venipuncture platelets are in a reversible activated state as a consequence of the mechanical stress ([@bib16]). In platelet populations prepared directly after blood sampling and stained for tubulin and acetylated tubulin ([Fig. 2, A and B](#fig2){ref-type="fig"}; and [Videos 2](http://www.jcb.org/cgi/content/full/jcb.201306085/DC1){#supp3} and [3](http://www.jcb.org/cgi/content/full/jcb.201306085/DC1){#supp4}), only 32 ± 12.6% were in the resting state, whereas the majority had a spherical shape with twisted MBs (68.2 ± 12.6%, seven independent experiments using blood from three different donors), reinforcing the idea that MB coiling induces sphere shape. After a recovery period of ∼2 h at RT, platelets had regained their flat disc shape and a normal MB ([Fig. 2 B](#fig2){ref-type="fig"} and Video 3). MB coiling was also observed when resting platelets in suspension were activated for 60 s with low concentrations of different agonists ([Fig. 2 B](#fig2){ref-type="fig"} and Video 3), whereas concentrations used in standard aggregation assays resulted in the smaller microtubule ring (not depicted).

![**MB coiling in activating platelets.** (A) 3D reconstruction of confocal z stacks of three representative examples of transiently activated platelets present in PRP prepared from freshly drawn blood, fixed, and stained for acetylated tubulin (AcTub). [Video 2](http://www.jcb.org/cgi/content/full/jcb.201306085/DC1){#supp5}. (B, left images) Transiently activated platelets present in PRP prepared from freshly drawn blood: either single platelets, platelets forming a small aggregate, or platelets of the same PRP, which have regained the resting state after a recovery period (120 min at RT). (right images) Platelets present in PRP prepared from buffy coats activated for 60 s with the following agonists: 6.25 µM arachidonic acid (AA), 25 nM ADP, and 0.01 U/ml thrombin (Th). Platelets are stained for α-tubulin. [Video 3](http://www.jcb.org/cgi/content/full/jcb.201306085/DC1){#supp6}. (C) Time-lapse video of a microtubule tracker-stained platelet spreading on a glass surface. Transmission (left) and fluorescence (right) images are taken simultaneously every 5 s. Three time points of the activation sequence are shown: disc shape with resting MB, sphere shape with coiled MB, and spread platelet with small microtubule ring. [Video 4](http://www.jcb.org/cgi/content/full/jcb.201306085/DC1){#supp7}. Time points are given in minutes and seconds. (D) Two time points of time-lapse videos of 3D reconstructions of confocal stacks of microtubule tracker-stained platelets activated with thrombin (0.017-U/ml final) and ADP (135-nM final) or treated with ATA (6.7-µM final). 3D projections are depth color coded as indicated. [Video 5](http://www.jcb.org/cgi/content/full/jcb.201306085/DC1){#supp8}. (E) Two time points of a time-lapse video of 3D reconstructions of confocal stacks of microtubule tracker-stained platelets activated with ADP (270-nM final). 3D projections are depth color coded as indicated. Shown are two different view angles to observe microtubules short cutting the coiled bundle (arrow). [Video 6](http://www.jcb.org/cgi/content/full/jcb.201306085/DC1){#supp9}. Bars, 2 µm.](JCB_201306085_Fig2){#fig2}

Furthermore, MB coiling is also observed during spreading of living microtubule tracker-stained platelets on a glass surface ([Fig. 2 C](#fig2){ref-type="fig"} and [Video 4](http://www.jcb.org/cgi/content/full/jcb.201306085/DC1){#supp10}). The fluorescent image of the time-lapse video shows that the MB started to coil (at a time point of 9 min and 50 s) when the transmission image shows the beginning of disc to sphere transition (at 10 min and 20 s, sphere shape is reached). We also used time-lapse video microscopy to follow platelet activation in suspension triggered with different agonists and observed MB coiling under all conditions tested ([Fig. 2, D and E](#fig2){ref-type="fig"}; and [Videos 5](http://www.jcb.org/cgi/content/full/jcb.201306085/DC1){#supp11} and [6](http://www.jcb.org/cgi/content/full/jcb.201306085/DC1){#supp12}).

Thus, MB coiling induces sphere shape and is part of the sequence of events leading to platelet activation. Although it has long been recognized that the MB is essential to keep the discoid shape of resting platelets ([@bib32]), this is the first description of MB coiling inducing the rapid disc to sphere transition of activating platelets, first described in 1965 ([@bib5]). Interestingly, highly similar microtubule coils have been described in limulus amebocytes and nucleated thrombocytes of nonmammalian vertebrates, indicating that this process is evolutionarily conserved ([@bib7]; [@bib15]).

Dynein is implicated in MB coiling
----------------------------------

One possible reason for MB coiling could be the limited available space either after actomyosin contraction or after MB extension. In favor of the latter hypothesis is the finding that MB length measurements after 3D reconstructions of confocal image stacks show that coiling MBs in freshly prepared platelets are statistically longer compared with flat MBs in resting platelets ([Fig. 3 A](#fig3){ref-type="fig"}). MB extension could be caused by dynein-induced sliding apart of microtubules similar to the dynein-mediated microtubule-sliding process responsible for proplatelet extension in megakaryocytes ([@bib18]). Such a mechanism is supported by our observation that transiently activated platelets with coiled MBs present in freshly drawn blood rapidly get back to their resting discoid shape upon dynein inhibition (27.3 ± 10.7% resting platelets in control vs. 67.2 ± 13% in EHNA-treated populations; five independent experiments, P \< 0.01; [Fig. 3 B](#fig3){ref-type="fig"}). Furthermore, we observed that EHNA treatment inhibits MB coiling induced by platelet activation with ADP ([Fig. S2 A](http://www.jcb.org/cgi/content/full/jcb.201306085/DC1){#supp13}).

![**Dynein-mediated MB extension induces its coiling.** (A) The MB length of resting platelets (PRP prepared from freshly drawn blood after a recovery period) and transiently activated platelets, present in PRP prepared from freshly drawn blood, was measured as described in the Materials and methods section. Platelets were grouped in five categories according to different coiling stages (stage 1, resting platelets, *n* = 66; stage 2, start of coiling, *n* = 31; stage 3, slightly coiled, *n* = 32; stage 4, more coiled, *n* = 33; and stage 5, maximum coiled, *n* = 16; data are presented as means ± SEM; \*, P \< 0.017; \*\*, P \< 0.38; \*\*\*, P \< 0.033; \*\*\*\*, P \< 0.0009). (B) Platelets prepared from freshly drawn blood with coiling MBs were diluted in PBS, 2.5 × 10^6^/ml, and incubated with or without EHNA (1-mM final) for 10 min at RT, fixed, and stained for α-tubulin (Tub). Arrows indicate platelets having simultaneously coiled and resting MBs. [Video 7](http://www.jcb.org/cgi/content/full/jcb.201306085/DC1){#supp14}. Bars, 2 µm.](JCB_201306085R_Fig3){#fig3}

However, although MB extension may be sufficient to induce MB coiling, it is not essential. Coiling is also observed when microtubule motor actions are bypassed by directly activating actomyosin contraction with calyculin (Fig. S2 B and [Video 10](http://www.jcb.org/cgi/content/full/jcb.201306085/DC1){#supp15}). MB length measurements using the tracker films also show that MBs can coil without significantly elongating ([Fig. S3](http://www.jcb.org/cgi/content/full/jcb.201306085/DC1){#supp16}). This may be attributed to the tracker stain in this case because it has an unexpected effect on platelets. Platelets stained with the taxol-based tracker kit have enhanced activation responses to ADP, whereas taxol-treated platelets have reduced responses (Fig. S2 A). One possible explanation for this result could be that the surfactant component of the tracker stain destabilizes actomyosin/microtubule connections, which may facilitate actomyosin contraction and bypass microtubule motor actions. Although our results demonstrate that MBs coil during platelet activation, they do not explain how the smaller ring structure observed in activated platelets might form.

Newly polymerizing microtubules form the smaller ring after actomyosin contraction
----------------------------------------------------------------------------------

To investigate the formation of the smaller ring structure, we based our strategy on the pioneering work by [@bib19]. They have shown that the MB is composed of stable and several actively polymerizing microtubules and that it can be stained with antibodies against acetylated and tyrosinated α-tubulin. Tyrosinated α-tubulin constitutes the pool of free tubulin subunits used by newly polymerizing microtubules ([@bib12]). To visualize simultaneously stable/acetylated, newly formed/tyrosinated, and total microtubules, we acquired confocal images of triple-stained platelets with MBs at different coiling stages. 3D reconstructions of individual stainings and merges are shown, and to better appreciate colocalizations, images were thresholded, and MBs were skeletonized. All three stainings colocalize in resting platelets and in platelets with slightly coiled MBs ([Fig. 4, A--C](#fig4){ref-type="fig"}; and [Video 8](http://www.jcb.org/cgi/content/full/jcb.201306085/DC1){#supp17}). In contrast, in platelets with strongly coiled MBs, newly formed microtubules take a new path by switching to the proximal part of the microtubule bundle, which leads to the formation of a smaller ring ([Fig. 4, D--F](#fig4){ref-type="fig"}; and [Video 9](http://www.jcb.org/cgi/content/full/jcb.201306085/DC1){#supp18}). The coiling stage when microtubules just start to use a new path ([Fig. 4 C](#fig4){ref-type="fig"}) reaching for the opposite side of the coiled bundle is also illustrated in Video 6 associated with [Fig. 2 E](#fig2){ref-type="fig"} (arrow).

![**Newly polymerizing microtubules form a smaller microtubule ring in activated platelets.** (A--F) Platelets with MBs at different coiling stages were triple immunostained for acetylated α-tubulin, tyrosinated α-tubulin, and total α-tubulin. Individual stainings as well as merges of 3D reconstructions of confocal z stacks are shown in the top images. The bottom images are generated from the different stainings after thresholding and skeletonizing of the MBs. For further details, see the legends of [Videos 8](http://www.jcb.org/cgi/content/full/jcb.201306085/DC1){#supp19} and [9](http://www.jcb.org/cgi/content/full/jcb.201306085/DC1){#supp20}. Bars, 2 µm.](JCB_201306085_Fig4){#fig4}

The more the coiled MB appears compressed, the smaller is the new ring and actomyosin contraction may come into play at this point. To test this, we treated resting platelets with the myosin inhibitor blebbistatin, shown previously to block actomyosin contraction in platelets ([@bib6]; [@bib13]) or used cytochalasin D to depolymerize the actin cytoskeleton. As expected, blebbistatin and cytochalasin D had no influence on the resting MB, and platelet activation by ADP leads to the smaller microtubule ring in control platelets. This process requires an intact actin cortex because pretreatment with cytochalasin D prevents the smaller ring formation. At a blebbistatin concentration of 25 µM, the smaller ring appears slightly larger compared with the control. Similar results using blebbistatin and cytochalasin pretreatment before thrombin-induced platelet activation have been obtained previously ([@bib26]). This has been interpreted as a requirement of actomyosin actions for the centripetal contraction of the MB to a smaller ring. However, careful examination of confocal image stacks reveals the presence of several platelets with coiled MBs, which is more evident when a blebbistatin concentration of 50 µM was used (47.4 ± 5.2%; [Fig. 5 A](#fig5){ref-type="fig"}). Thus, actomyosin contraction is required to compress the coiled MB, and its efficiency may decide about the fate of activating platelets. In the case of sustained actomyosin contraction, platelets may proceed to full, irreversible activation, and microtubules, polymerizing along the coiled, compressed MB, will form the smaller ring structure. In transiently activated platelets, actomyosin contraction is not maintained, and the new path taken by actively polymerizing microtubules will attain the size of a resting MB, which leads to platelets having simultaneously a coiled/elongated and a flat/resting MB ([Fig. 4 D](#fig4){ref-type="fig"}). Such platelets have been described previously by [@bib4]. They can be found sporadically in populations of resting platelets (1--5%; not depicted) and more importantly in platelet populations prepared from freshly drawn blood after dynein inhibition, when they come back to the resting state ([Fig. 3 B](#fig3){ref-type="fig"}, arrows). The flat, newly polymerized MB may be progressively reacetylated, whereas the coiled, acetylated bundle, no longer used by newly polymerizing microtubules, might be rapidly depolymerized and deacetylated. This could explain the high degree of heterogeneity of MB acetylation in resting platelets. A low acetylation level may be indicative of a recent transient activation event. The rapid tubulin deacetylation observed during platelet activation ([@bib24]; [@bib3]) may also depend on the depolymerization of the coiled part of the MB to give the deacetylase HDAC6 access to its preferred substrate, unpolymerized tubulin ([@bib17]). Dynein-induced MB coiling takes place when microtubules are acetylated ([Fig. 1 D](#fig1){ref-type="fig"} and [Fig. 2 A](#fig2){ref-type="fig"}). Like for dynein-mediated cargo transport ([@bib8]), acetylation may enhance dynein actions, which could speed up coiling and explain the faster spreading capacity of platelets with hyperacetylated MBs ([@bib24]).

![**Actomyosin contraction compresses the coiled MB.** (A) Platelets were diluted in PBS, 2.5 × 10^6^/ml, and pretreated with or without 25 or 50 µM blebbistatin (blebbi) or 1 µg/ml cytochalasin D for 30 min at RT. Platelets were then either activated with ADP (2.5-µM final) for 10 min at RT (bottom) or not activated (top), fixed, and stained for α-tubulin. Bars, 2 µm. (B) Putative sequence of events leading to platelet activation (to simplify, only two microtubules are shown in disc-shaped platelets).](JCB_201306085_Fig5){#fig5}

The combined results allow us to deduce a putative model ([Fig. 5 B](#fig5){ref-type="fig"}) to explain the cross talk between the actin and tubulin part of the cytoskeleton, previously shown to be also important for platelet size determination ([@bib29]). The absolute requirement of an intact actin cytoskeleton for MB coiling may suggest that it serves as support for dynein-mediated microtubule sliding. Similar to nucleated cells ([@bib30]; [@bib14]), dynein may be anchored to the actin cortex and slide microtubules apart once an activation signal reduces kinesin counteractions. Elongation of the MB then leads to its coiling, which might tear on (or rupture) microtubule--cortex interactions. This could be sensed by actomyosin as a signal to contract and compress the coiled MB.

In conclusion, this study sheds a completely new light on the events leading to platelet activation. The information that microtubule motor actions play a role in platelet physiology and are possibly regulated by microtubule acetylation highlights new directions for the development of therapeutic strategies able to modify platelet function. Furthermore, this study investigates cytoskeletal elements in a physiological cellular context in the absence of the nucleus and centrosomes. It reveals a tight interplay between the actomyosin and the microtubule part of the cytoskeleton governing rapid cell shape changes.

Materials and methods
=====================

Reagents and antibodies
-----------------------

The following antibodies were used: mouse anti--acetylated tubulin (clone 6-11B-1; T6793; Sigma-Aldrich), mouse anti--α-tubulin (clone B-5-1-2; T5168; Sigma-Aldrich), monoclonal rabbit anti--α-tubulin (clone EP1332Y; 04--1117; EMD Millipore), monoclonal rat anti--tyrosinated α-tubulin (gift of A. Andrieux, Grenoble Institut des Neurosciences, Grenoble, France), rabbit anti--kinesin heavy chain (AKINO1; Cytoskeleton, Inc.), mouse anti--dynein intermediate chain (clone 74.1; MAB1618; EMD Millipore), nonimmune rabbit IgGs (I5006; Sigma-Aldrich), Alexa Fluor 488 goat anti--mouse IgG (A11029; Invitrogen), Alexa Fluor 488 goat anti--rabbit IgG (A11034; Invitrogen), Alexa Fluor 546 goat anti--mouse IgG (A11030; Invitrogen), Alexa Fluor 546 goat anti--rabbit IgG (A11035; Invitrogen), Alexa Fluor 546 goat anti--rat IgG (A11081; Invitrogen), Alexa Fluor 647 goat anti--rabbit IgG (A21245; Invitrogen), HRP goat anti--rabbit IgG (P0448; Dako), and HRP goat anti--mouse IgG (P0447; Dako). The following reagents were used: phalloidin-rhodamine (Sigma-Aldrich), Tubulin Tracker (Invitrogen), cytochalasin D (Sigma-Aldrich), poly-[d]{.smallcaps}-lysine (Sigma-Aldrich), thrombin (Sigma-Aldrich), arachidonic acid (Helena Biosciences), and ADP (Helena Biosciences).

Cell culture
------------

The human lung carcinoma cell line A549 and the human megakaryocytic cell line CHRF-288-11 were cultured in RPMI 1640/10% FCS.

Preparation of human platelet-rich plasma (PRP)
-----------------------------------------------

Nontherapeutic buffy coats were diluted with an equal volume of PBS and centrifuged for 10 min, 400 *g*, at RT, and the upper phase corresponding to the PRP was collected. Alternatively, PRP from freshly drawn citrated blood (needle Eclipse \[BD\]; Vacutainer \[BD\]) was prepared identically but without prior PBS dilution.

Detection of microtubule motor proteins in cell lysates
-------------------------------------------------------

A549 cells, megakaryocyte precursor cells (CHRF-288-11), and platelets prepared from buffy coats were lysed in sample buffer for SDS-PAGE and boiled for 5 min. Samples were run on a 10% gel and transferred onto polyvinylidene difluoride membranes. Motor protein subunits were revealed with a pan-anti--kinesin heavy chain and an anti--dynein intermediate chain antibody.

Spreading assay
---------------

Platelets are diluted in PBS and pipetted into 24-well plates with coverslips (10^6^/400 µl/well). Plates are then centrifuged for 3 min, 600 *g*, at RT to assure simultaneous platelet contact with glass surfaces, allowing synchronized spreading. Platelets are fixed in 4% neutral formalin after the indicated spreading times. For the resting state, platelets are first fixed and then pipetted into 24-well plates with glass coverslips (coated with 0.02 mg/ml poly-[d]{.smallcaps}-lysine for 1 h at RT) and centrifuged for 5 min, 600 *g*, at RT.

Motor inhibitor treatments
--------------------------

For kinesin inhibition, platelets were diluted in PBS to a concentration of 2.5 × 10^6^/ml and then incubated with freshly prepared ATA (Sigma-Aldrich) at a final concentration of 10 µM for initial experiments and at 40 µM for quantification experiments to account for different plasma concentrations caused by varying platelet counts of individual donors and potential absorption of the drug by plasma proteins. For dynein inhibition, platelets were incubated with 1 mM EHNA (Sigma-Aldrich). For myosin II inhibition, we used (−)-blebbistatin (EMD Millipore), which was prepared as a 25-mM stock solution in DMSO and then diluted under vigorous agitation into PBS preheated to 45°C to avoid precipitation as previously described ([@bib27]). The solution was then centrifuged before addition of platelets.

Immunofluorescence
------------------

Fixed platelets on coverslips were permeabilized with PBS/0.2% Triton X-100 for 15 min at RT and then incubated with blocking buffer (3% BSA and 10% goat serum in PBS) for 1 h at RT. Coverslips were then incubated for 2 h with primary antibodies diluted in blocking buffer and then washed twice with PBS and once with PBS/0.2% Triton X-100 and incubated with secondary antibodies diluted in blocking buffer for 2 h at RT. After three washing steps, coverslips were mounted on glass slides using Mowiol.

Image acquisition and processing
--------------------------------

Fluorescent images were acquired and processed as follows for each figure. For [Fig. 1 B](#fig1){ref-type="fig"} and Fig. S1 A, a wide-field epifluorescence microscope (BX41; Olympus), objective Plan 100×/1.25 NA oil, camera (DP70; Olympus), and acquisition software (analySIS; Olympus) were used. For [Fig. 1 C](#fig1){ref-type="fig"}, a wide-field epifluorescence microscope (BX41), objective Plan 100×/1.25 NA oil, camera (DP70), and acquisition software (analySIS) were used. Merges were produced using Photoshop (Adobe). For [Fig. 1 D](#fig1){ref-type="fig"}, a confocal laser-scanning microscope (LSM 510; Carl Zeiss) objective Plan Apochromat 100×/1.4 NA oil, and acquisition software (LSM 510) were used. The 3D reconstitution was produced using MetaMorph (Molecular Devices). For [Fig. 2 A](#fig2){ref-type="fig"}, a confocal laser-scanning microscope (LSM 510), objective Plan Apochromat 100×/1.4 NA oil, and acquisition software (LSM 510) were used. The 3D reconstitution was produced using ImageJ 3D Project (National Institutes of Health). For [Fig. 2 B](#fig2){ref-type="fig"}, [Fig. 3 B](#fig3){ref-type="fig"}, [Fig. 5 A](#fig5){ref-type="fig"}, and Fig. S2 A, a confocal laser-scanning microscope (LSM 710; Carl Zeiss), objective Plan Apochromat 63×/1.4 NA oil, and acquisition software (Zen 2010; Carl Zeiss) were used. Image processing was performed using the custom ImageJ macro Marginal Band 3D Analysis ([Supplemental material](http://www.jcb.org/cgi/content/full/jcb.201306085/DC1){#supp21}), and the 3D reconstitution was performed with ImageJ 3D Project. For [Fig. 2 C](#fig2){ref-type="fig"}, a confocal laser-scanning microscope (LSM 510), objective Plan Apochromat 100×/1.4 NA oil differential interference contrast III, and acquisition software (LSM 510) were used. Image processing was performed with MetaMorph. For acquisition details, see the legend of Video 4. For [Fig. 2 (D and E)](#fig2){ref-type="fig"} and Fig. S2 B, a confocal laser-scanning microscope (LSM 710), objective Plan Apochromat 63×/1.4 NA oil, and acquisition software (Zen 2010) were used. 3D reconstitution and depth coding were performed using the custom ImageJ macro 3D Project Color Depth Coding ([Supplemental material](http://www.jcb.org/cgi/content/full/jcb.201306085/DC1){#supp22}). For acquisition details, see the legends of Videos 5, 6, and 10. For [Fig. 3 A](#fig3){ref-type="fig"}, a confocal laser-scanning microscope (LSM 710), objective Plan Apochromat 63×/1.4 NA oil, and acquisition software (Zen 2010) were used. Image processing and 3D reconstitution were performed using the custom ImageJ macro Marginal Band 3D Analysis. For [Fig. 4 (A--F)](#fig4){ref-type="fig"}, a confocal laser-scanning microscope (LSM 710), objective Plan Apochromat 63×/1.4 NA oil, and acquisition software (Zen 2010) were used. 3D reconstitutions in the top images were produced using ImageJ 3D Project, and skeletonization of MBs in the bottom images were obtained using the custom ImageJ macro Marginal Band 3D Analysis.

3D MB length measurements
-------------------------

The length of MBs was measured using the custom ImageJ macro Marginal Band 3D Analysis. In brief, after acquisition of confocal z stacks, the stacks were first interpolated using the processing software ImageJ to obtain isotropic voxels ([@bib1]). Then, a band pass filter was applied using the difference of two Gaussian filters. With the first filter, the original stack was smoothed by convolving with a 3D Gaussian kernel of standard deviation s1. Using a second filter, the original stack was smoothed with a Gaussian kernel of standard deviation s2, with s2 \< s1 (here, we used s1 = 7 and s2 = 2). The difference of Gaussians stack was computed from the difference of the two smoothed stacks. After thresholding, the platelet skeleton was obtained and measured with the ImageJ plugin AnalyzeSkeleton, which allows pruning and loop closing in a user-defined manner for each platelet ([@bib2]).

Delivery of antibodies into living platelets
--------------------------------------------

Antibodies were introduced into platelets using the protein delivery kit (Chariot; Active Motif). In brief, 2 µg antibodies in 50 µl PBS was incubated with 2 µl Chariot in 50 µl H~2~O for 30 min at RT. 10^6^ platelets in 100 µl PBS were then added to the antibody/Chariot mix and incubated for 1 h at RT to allow antibody internalization before being used in the spreading assay.

MB staining of living platelets
-------------------------------

For the spreading assay, PRP (2 ml prepared from buffy coats) was centrifuged for 10 min, 900 *g*, at RT. The platelet pellet was resuspended in 1 ml PBS containing the reagent (taxol-based compound coupled to a fluorochrome; Tubulin Tracker) at a final concentration of 500 nM and incubated for 30 min at 37°C before time-lapse video microscopy. For suspension activations, platelets were diluted in PBS, 1.6 × 10^7^/ml, and 1 µl tracker reagent was added per milliliter of platelet suspension. After 30--60 min of incubation at RT, the suspension was diluted with an equal volume of PBS, and 500 µl was pipetted into 4-well slides (Lab-Tek; Thermo Fisher Scientific). Platelets were imaged at RT and activated by the addition of one drop (36 µl) of agonist solution to obtain final concentrations as indicated.

Video microscopy
----------------

Imaging of spreading platelets by fluorescence and differential interference contrast was performed using the inverted confocal microscope (LSM 510) equipped with a 100×/1.4 Plan Apochromat objective. The pinhole was adjusted to 2 arbitrary units, and the confocal plane was positioned slightly above the glass surface. The fluorescence excitation at 488 nm was attenuated to 0.2% acousto-optic tunable filter transmission. Platelets were allowed to sediment on chambered coverslips (Lab-Tek) at RT. Images were acquired every 5 s.

3D confocal video microscopy was performed in single-photon detection mode with a confocal microscope (LSM 710 ConfoCor 3), 63×/1.4 NA Plan Apochromat objective, long pass 505-nm emission filter, and single-photon avalanche photodiode detector (ConfoCor 3). The 488-nm excitation power at the objective output was only 30 nW (0.005% acousto-optic tunable filter transmission), ensuring no fluorescence photobleaching throughout the whole time-lapse acquisition and no laser-induced platelet activation as compared with the nonirradiated zones at the end of the experiment. The pinhole was closed to 1 arbitrary unit, and the voxel size was set to 66 × 66 × 500 nm with a pixel dwell time of 6.3 µs. Six planes spaced by 0.5 µm were imaged in each z stack. Image processing and color depth coding were made with the custom ImageJ macro 3D Project Color Depth Coding.

Quantification
--------------

For all platelet quantification data, \>50 platelets were analyzed per experiment after confocal z-stack acquisitions. Data are expressed in percentages as means ± SEM obtained from several individual experiments as indicated.

Online supplemental material
----------------------------

Fig. S1 shows the quantification of experiments presented in [Fig. 1 (B and C)](#fig1){ref-type="fig"} on the inhibition of microtubule motor proteins. Fig. S2 shows MB coiling induced by different concentrations of ADP after treatment of platelets with the dynein inhibitor, the Tubulin Tracker, or taxol and two time points of time-lapse videos of microtubule tracker-stained platelets with MB coiling induced by calyculin. Fig. S3 shows MB length measurements at successive time points during MB coiling shown in the time-lapse videos Video 5 after ADP activation and kinesin inhibition and Video 6 after ADP activation. Video 1 ([Fig. 1 D](#fig1){ref-type="fig"}) shows a 360° rotation of MBs induced to coil by kinesin inhibition. Video 2 ([Fig. 2 A](#fig2){ref-type="fig"}) shows a 360° rotation of acetylated, coiled MBs in transiently activated platelets. Video 3 ([Fig. 2 B](#fig2){ref-type="fig"}) shows a 360° rotation of coiled MBs in platelets activated by mechanical stress, arachidonic acid, ADP, or thrombin. Video 4 ([Fig. 2 C](#fig2){ref-type="fig"}) shows a time-lapse video of MB coiling during platelet spreading. Video 5 ([Fig. 2 D](#fig2){ref-type="fig"}) shows time-lapse videos of MB coiling triggered by thrombin, ADP, or kinesin inhibition. Video 6 ([Fig. 2 E](#fig2){ref-type="fig"}) shows a time-lapse video at two different view angles of MB coiling after platelet activation with ADP illustrating the coiling stage at which newly polymerized microtubules shortcut the coiled bundle. Video 7 ([Fig. 3 B](#fig3){ref-type="fig"}) shows a 360° rotation of MBs present in platelets prepared from freshly drawn blood with and without dynein inhibition. Video 8 ([Fig. 4, A--C](#fig4){ref-type="fig"}) shows a 360° rotation of platelets with resting or slightly coiled MBs triple stained for acetylated, tyrosinated, and total tubulin as well as the same images reduced to one voxel skeletons. Video 9 ([Fig. 4, D--F](#fig4){ref-type="fig"}) shows a 360° rotation of platelets with strongly coiled MBs triple stained for acetylated, tyrosinated, and total tubulin as well as the same images reduced to one voxel skeletons. Video 10 (Fig S2 B) shows time-lapse videos of MB coiling induced by activation of actomyosin contraction. A source code for a custom ImageJ macro for Marginal Band 3D Analysis, with a toolset for image processing, 3D viewing, skeletonization of MBs, manual skeleton editing, and MB length measurements is provided online as a text file. A source code for a custom ImageJ macro for 3D Project Color Depth Coding, with a tool for depth color coding of 3D confocal time-lapse series and visualization at different view angles is provided online as a text file. Online supplemental material is available at <http://www.jcb.org/cgi/content/full/jcb.201306085/DC1>. Additional data are available in the JCB DataViewer at <http://dx.doi.org/10.1083/jcb.201306085.dv>.
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